Annoviant announced today that it received a $1.85 million NIH grant to help further the development and commercialization of its TxGuard.
Atlanta-based Annoviant’s latest grant for the TxGuard pulmonary-valved conduit represents a continuation of the Phase I Small Business Technology Transfer (STTR) grant the company received in 2019, according to a news release.
Get the full story at our sister site, Medical Design & Outsourcing.